Published On : September 2026
A buyer assuming therapy indication alone predicts implant setting is overlooking the variable that actually routes a case in this market.
Within the vagus nerve stimulator market, device type is the variable that most shapes implant setting selection, since an implantable system generally requires a different care pathway than a non-invasive, externally applied system regardless of which therapy indication is involved.
This page describes three implant setting categories and seven customer type categories strictly as market segments.
It provides no surgical, fitting or procedural guidance, and makes no claim about clinical outcome for any setting or provider type.
An implantable system generally requires inpatient or outpatient implantation, or evaluation at an ambulatory surgical centre, distinct from the non-invasive system's simpler fitting pathway.
That device-type-first pattern is why care provider teams experienced in this market frame implant setting conversations around device type rather than around therapy indication label alone.
Seven customer type categories complete the picture once implant setting is established, spanning academic medical centres, neurology specialty hospitals, neurosurgery centres, comprehensive epilepsy centres, psychiatric treatment centres, ambulatory surgical centres and veterans healthcare systems.
Academic medical centres and comprehensive epilepsy centres together represent the customer type categories most frequently paired with implantable device types, reflecting their established surgical and monitoring infrastructure.
Psychiatric treatment centres are generally associated with treatment-resistant depression referrals specifically, distinct from the broader indication mix typical of comprehensive epilepsy centres.
For buyers, establishing device type for a specific case is a more reliable starting point than therapy indication label alone when planning implant setting capacity.
For manufacturers, implant setting and customer type breadth across all three and seven categories respectively widens the addressable share of any care network's evaluation and treatment pathway.
This device-type-first pattern holds across every implant setting this report tracks, since a care network's initial mapping of device type generally precedes any discussion of which specific facility a case is routed to.
A care network that plans implant setting capacity around therapy indication alone risks under-provisioning inpatient or outpatient implantation slots when device type mix shifts toward implantable systems for a new indication.
This device-type-first planning approach is increasingly common among networks managing more than one therapy indication simultaneously.
For manufacturers entering a new region, understanding local device-type-to-setting patterns before launch reduces the risk of miscalibrated commercial planning.
Inpatient implantation and outpatient implantation form the two most established implant setting categories tracked in this report.
Both are named here as market categories, and this page states nothing about how either implantation pathway is performed.
Inpatient implantation is generally specified where a centre's treatment pathway favours extended post-procedure observation, distinct from the same-day discharge pathway typical of outpatient implantation.
Outpatient implantation is generally associated with more established implantable device categories, reflecting greater physician familiarity with the procedure pathway.
Commercially, inpatient and outpatient implantation settings generally involve different capital equipment and staffing considerations for a given care provider type.
For manufacturers, supporting both inpatient and outpatient implantation pathways widens the addressable share of any care network's surgical capacity.
For buyers, confirming which implant setting categories a centre's surgical team maintains established capability for is a reasonable starting point before evaluating a new device programme.
A centre newly adding outpatient implantation capability typically starts with its most established device type category before extending the same-day pathway to newer or less familiar systems.
Staffing models for inpatient implantation generally differ from outpatient implantation, reflecting the extended observation window the inpatient pathway requires.
Ambulatory surgical centres complete the implant setting dimension tracked in this report.
This category is named here as a market segment, and this page states nothing about the specific procedures performed at any named facility type.
Ambulatory surgical centres are generally associated with more established, lower-complexity implantation pathways, distinct from the extended observation pathway typical of inpatient implantation.
Commercially, ambulatory surgical centre capacity growth is tied to broader outpatient implantation adoption trends across the device type categories this report tracks.
For manufacturers, ambulatory surgical centre relationships are a meaningful differentiator given the broader shift toward outpatient-capable implantation pathways tracked among this market's strategic developments.
Buyers evaluating this setting category generally weigh a facility's device-specific procedural volume as heavily as its general surgical capability.
Ambulatory surgical centres considering their first VNS programme typically start with the device type category already most familiar to their existing surgical staff.
Facility-level device-specific procedural volume data, where available, is generally a more reliable indicator of established capability than general surgical caseload alone.
|
PROCUREMENT INSIGHT Ambulatory surgical centres expanding into their first VNS programme typically negotiate procurement terms around the single device type category their surgical staff is already familiar with, rather than across the full device type range this report tracks, a pattern that narrows early-stage supplier conversations more than buyers often expect. |
Academic medical centres and neurology specialty hospitals form a further customer type grouping tracked in this report.
Both are named here as market categories, and this page states nothing about the clinical outcomes achieved at either facility type.
Academic medical centres generally combine clinical evaluation with academic research activity, distinct from the more clinically focused pathway typical of neurology specialty hospitals.
Neurology specialty hospitals are generally associated with a narrower device and indication focus than academic medical centres, reflecting their more specialised care model.
Commercially, academic medical centres more frequently participate in clinical trial programmes than neurology specialty hospitals, given their academic research orientation.
For manufacturers, academic medical centre relationships are a meaningful differentiator given the pace of clinical trial programmes tracked among this market's strategic developments.
Buyers evaluating referral pathways for either facility type generally weigh academic research participation alongside general clinical evaluation capability.
A neurology specialty hospital expanding into a second therapy indication often looks to an academic medical centre's established referral pathway as a reference point before building its own.
Academic research participation at a given centre can also shape which technology platform categories that centre is positioned to evaluate first.
Neurosurgery centres and comprehensive epilepsy centres form a further customer type grouping tracked in this report.
Both are named here as market categories, and this page states nothing about the surgical outcomes achieved at either facility type.
Neurosurgery centres are generally associated with the broadest range of implantable device types, reflecting their established surgical infrastructure across multiple neurological indications.
Comprehensive epilepsy centres, meanwhile, concentrate most heavily on the therapy indications these provider types treat, particularly drug-resistant epilepsy, given the specialised monitoring infrastructure this facility type maintains.
Commercially, this grouping anchors the deepest clinical evidence portfolio of any customer type category tracked in this report, given the established surgical and monitoring infrastructure both facility types maintain.
For manufacturers, neurosurgery centre and comprehensive epilepsy centre relationships continue to anchor the broadest share of implantable device referral volume in this market.
Buyers comparing these two facility types generally weigh comprehensive epilepsy centre indication depth against neurosurgery centre indication breadth, depending on the referral in question.
A comprehensive epilepsy centre's monitoring infrastructure is generally purpose-built for drug-resistant epilepsy specifically, which can make it a less natural fit for a treatment-resistant depression or migraine management referral even when surgical capability overlaps.
Neurosurgery centres, with their broader indication reach, more frequently serve as a shared surgical resource across several referring specialties at once.
Psychiatric treatment centres and veterans healthcare systems complete the customer type dimension tracked in this report.
Both are named here as market categories, and this page states nothing about the psychiatric or rehabilitation outcomes achieved at either facility type.
Psychiatric treatment centres are generally associated with treatment-resistant depression referrals specifically, distinct from the broader neurological indication mix typical of the other customer type categories tracked on this page.
Veterans healthcare systems are generally associated with a government healthcare procurement pathway, reflecting their institutional purchasing structure.
Because procurement structure varies so much by customer type, the procurement models these care settings typically use is a useful starting point before assuming any two facility types purchase VNS systems the same way.
For manufacturers, psychiatric treatment centre and veterans healthcare system relationships require distinct commercial approaches given their differing procurement and referral structures.
Buyers evaluating either facility type generally weigh institutional procurement pathway fit as heavily as clinical evaluation capability.
A veterans healthcare system's government healthcare procurement pathway can extend purchase timelines relative to a private hospital's direct procurement pathway, a planning consideration for manufacturers entering this customer type category.
Psychiatric treatment centres new to VNS referral pathways often coordinate closely with a partnering neurosurgery centre or academic medical centre for the implantation itself.
Three implant setting categories are tracked in this report: inpatient implantation, outpatient implantation and ambulatory surgical centres.
Inpatient implantation involves extended post-procedure observation, while outpatient implantation generally allows same-day discharge. Both are named here as implant setting market categories.
Seven categories are tracked: academic medical centres, neurology specialty hospitals, neurosurgery centres, comprehensive epilepsy centres, psychiatric treatment centres, ambulatory surgical centres and veterans healthcare systems.
Because an implantable system generally requires a different care pathway than a non-invasive system, regardless of which therapy indication is involved, making device type the variable that most shapes implant setting selection.
Psychiatric treatment centres are generally associated with treatment-resistant depression referrals specifically, a customer type category tracked separately from the broader neurological facility types in this report.